CERTIFICATION OF ENROLLMENT

SUBSTITUTE HOUSE BILL 2640

Chapter 178, Laws of 2006

59th Legislature 2006 Regular Session

TAX INCENTIVES -- BIOTECHNOLOGY PRODUCTS

EFFECTIVE DATE: 7/1/06

Passed by the House February 10, 2006 Yeas 93 Nays 5

FRANK CHOPP

Speaker of the House of Representatives

Passed by the Senate March 8, 2006 Yeas 43 Nays 3

CERTIFICATE

I, Richard Nafziger, Chief Clerk of the House of Representatives of the State of Washington, do hereby certify that the attached is **SUBSTITUTE HOUSE BILL 2640** as passed by the House of Representatives and the Senate on the dates hereon set forth.

RICHARD NAFZIGER

BRAD OWEN

President of the Senate

Approved March 23, 2006.

FILED

March 23, 2006 - 10:15 a.m.

Chief Clerk

CHRISTINE GREGOIRE

Governor of the State of Washington

Secretary of State State of Washington

SUBSTITUTE HOUSE BILL 2640

Passed Legislature - 2006 Regular Session

By House Committee on Finance (originally sponsored by Representatives B. Sullivan, McCoy, O'Brien, Haler, Sells, Morris, Ericks, Strow and Dunn)

59th Legislature

READ FIRST TIME 2/7/06.

State of Washington

AN ACT Relating to biotechnology product and medical device manufacturing tax incentives; amending RCW 82.32.600; adding a new section to chapter 82.32 RCW; adding a new chapter to Title 82 RCW; providing an effective date; and providing an expiration date.

5 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON:

6 The legislature finds that the state's NEW SECTION. Sec. 1. 7 economy is increasingly dependent on the expansion of knowledge-based 8 sectors, including the life sciences. The legislature also finds that 9 commercial enterprises in the life sciences create high-wage, 10 high-skilled jobs that are part of the state's effort to encourage 11 economic diversification and stability. However, the legislature also 12 finds that commercial life sciences businesses, particularly 13 biotechnology and medical device manufacturing, product significant costs associated with capital infrastructure and job 14 15 training often years before a product is licensed for marketing or a facility is licensed for manufacturing by governmental agencies in the 16 United States and abroad. The legislature also finds that current 17 state tax policy discourages the growth of these companies in two ways: 18 19 (1) Washington state's higher rate of taxation compared with other

SHB 2640.SL

2006 Regular Session

states and nations encourages the export of intellectual property and commercial operations out of Washington; and (2) taxing these businesses before facilities, or products produced therein, are licensed for marketing by regulatory agencies.

The legislature further finds that targeted tax incentives may encourage the formation, expansion, and retention of commercial operations within the life sciences sector. The legislature also finds that tax incentives should be subject to the same rigorous requirements for efficiency and accountability as are other expenditure programs, and that tax incentives should therefore be focused to provide the greatest possible return on the state's investment.

For these reasons, the legislature hereby establishes a tax deferral program for commercial manufacturing facilities in this sector. The legislature declares that these limited programs serve the vital public purposes of incenting expenditures in commercial life science operations and the development of employment opportunities in this state. The legislature further declares its intent to create a contract within the meaning of Article I, section 23 of the state Constitution as to those businesses that make capital investments in consideration of the tax deferral program established in this chapter.

- NEW SECTION. Sec. 2. Unless the context clearly requires otherwise, the definitions in this section apply throughout this chapter.
 - (1) "Applicant" means a person applying for a tax deferral under this chapter.
 - (2) "Biotechnology" means a technology based on the science of biology, microbiology, molecular biology, cellular biology, biochemistry, or biophysics, or any combination of these, and includes, but is not limited to, recombinant DNA techniques, genetics and genetic engineering, cell fusion techniques, and new bioprocesses, using living organisms, or parts of organisms.
 - (3) "Biotechnology product" means any virus, therapeutic serum, antibody, protein, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, or analogous product produced through the application of biotechnology that is used in the prevention, treatment, or cure of diseases or injuries to humans.
 - (4) "Department" means the department of revenue.

1 (5)(a) "Eligible investment project" means an investment in 2 qualified buildings or qualified machinery and equipment, including 3 labor and services rendered in the planning, installation, and 4 construction of the project.

5

6 7

8

9

11

1213

14

15

16 17

18

22

23

24

25

26 27

28

29

30

3132

33

34

- (b) The lessor or owner of a qualified building is not eligible for a deferral unless:
- (i) The underlying ownership of the buildings, machinery, and equipment vests exclusively in the same person; or
- (ii)(A) The lessor by written contract agrees to pass the economic benefit of the deferral to the lessee;
 - (B) The lessee that receives the economic benefit of the deferral agrees in writing with the department to complete the annual survey required under section 8 of this act; and
 - (C) The economic benefit of the deferral passed to the lessee is no less than the amount of tax deferred by the lessor and is evidenced by written documentation of any type of payment, credit, or other financial arrangement between the lessor or owner of the qualified building and the lessee.
- 19 (6)(a) "Initiation of construction" means the date that a building 20 permit is issued under the building code adopted under RCW 19.27.031 21 for:
 - (i) Construction of the qualified building, if the underlying ownership of the building vests exclusively with the person receiving the economic benefit of the deferral;
 - (ii) Construction of the qualified building, if the economic benefits of the deferral are passed to a lessee as provided in subsection (5)(b)(ii)(A) of this section; or
 - (iii) Tenant improvements for a qualified building, if the economic benefits of the deferral are passed to a lessee as provided in subsection (5)(b)(ii)(A) of this section.
 - (b) "Initiation of construction" does not include soil testing, site clearing and grading, site preparation, or any other related activities that are initiated before the issuance of a building permit for the construction of the foundation of the building.
- 35 (c) If the investment project is a phased project, "initiation of construction" shall apply separately to each phase.
 - (7) "Manufacturing" has the meaning provided in RCW 82.04.120.

- 1 (8) "Medical device" means an instrument, apparatus, implement, 2 machine, contrivance, implant, in vitro reagent, or other similar or 3 related article, including any component, part, or accessory, that is 4 designed or developed and:
 - (a) Recognized in the national formulary, or the United States pharmacopeia, or any supplement to them;
 - (b) Intended for use in the diagnosis of disease, or in the cure, mitigation, treatment, or prevention of disease or other conditions in human beings or other animals; or
 - (c) Intended to affect the structure or any function of the body of man or other animals, and which does not achieve any of its primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of any of its principal intended purposes.
 - (9) "Person" has the meaning provided in RCW 82.04.030.
 - (10) "Qualified buildings" means construction of new structures, and expansion or renovation of existing structures for the purpose of increasing floor space or production capacity used for biotechnology product manufacturing or medical device manufacturing activities, offices, commercial including plant laboratories for process development, quality assurance and quality control, and warehouses or other facilities for the storage of raw material or finished goods if the facilities are an essential or an integral part of a factory, plant, or laboratory used for biotechnology product manufacturing or medical device manufacturing. If a building is used partly for biotechnology product manufacturing or medical device manufacturing and partly for other purposes, the applicable tax deferral shall be determined by apportionment of the costs of construction under rules adopted by the department.
 - (11) "Qualified machinery and equipment" means all new industrial and research fixtures, equipment, and support facilities that are an integral and necessary part of a biotechnology product manufacturing or medical device manufacturing operation. "Qualified machinery and equipment" includes: Computers; software; data processing equipment; laboratory equipment; manufacturing components such as belts, pulleys, shafts, and moving parts; molds, tools, and dies; operating structures; and all equipment used to control or operate the machinery.

6 7

8

10

11 12

13

14

15

16 17

18

19

20

21

22

2324

25

2627

2829

3031

32

33

34

3536

- 1 (12) "Recipient" means a person receiving a tax deferral under this 2 chapter.
- NEW SECTION. Sec. 3. Application for deferral of taxes under this 3 4 chapter must be made and approved before initiation of the construction of the investment project or acquisition of equipment or machinery. 5 6 The application shall be made to the department in a form and manner 7 prescribed by the department. The application shall contain information regarding the location of the investment project, the 8 applicant's average employment in the state for the prior year, 9 estimated or actual new employment related to the project, estimated or 10 11 actual wages of employees related to the project, estimated or actual 12 costs, time schedules for completion and operation, and other information required by the department. The department shall rule on 13 the application within sixty days. 14
- NEW SECTION. **Sec. 4.** (1) The department shall issue a sales and use tax deferral certificate for state and local sales and use taxes due under chapters 82.08, 82.12, and 82.14 RCW for each eligible investment project.
- 19 (2) No certificate may be issued for an investment project that has 20 already received a deferral under chapter 82.60 or 82.63 RCW or this 21 chapter.
- 22 (3) The department shall keep a running total of all deferrals 23 granted under this chapter during each fiscal biennium.
 - (4) This section expires January 1, 2017.

2829

30

31

32

- NEW SECTION. Sec. 5. (1) Except as provided in subsection (2) of this section and section 8 of this act, taxes deferred under this chapter need not be repaid.
 - (2)(a) If, on the basis of the survey under section 8 of this act or other information, the department finds that an investment project is used for purposes other than qualified biotechnology product manufacturing or medical device manufacturing activities at any time during the calendar year in which the eligible investment project is certified by the department as having been operationally completed, or at any time during any of the seven succeeding calendar years, a

1 portion of deferred taxes shall be immediately due and payable 2 according to the following schedule:

3	Year in which use occurs	% of deferred taxes due
4	1	100%
5	2	87.5%
6	3	75%
7	4	62.5%
8	5	50%
9	6	37.5%
10	7	25%
11	8	12.5%

- (b) If a recipient of the deferral fails to complete the annual survey required under section 8 of this act by the date due, the amount of deferred tax specified in section 8(6) of this act shall be immediately due and payable. If the economic benefits of the deferral are passed to a lessee as provided in section 2 of this act, the lessee is responsible for payment to the extent the lessee has received the economic benefit.
- (3) For a violation of subsection (2)(a) of this section, the department shall assess interest at the rate provided for delinquent taxes, but not penalties, retroactively to the date of deferral. The debt for deferred taxes shall not be extinguished by insolvency or other failure of the recipient. Transfer of ownership does not terminate the deferral. The deferral is transferred, subject to the successor meeting the eligibility requirements of this chapter, for the remaining periods of the deferral.
- (4) Notwithstanding subsection (2) of this section, deferred taxes on the following need not be repaid:
- (a) Machinery and equipment, and sales of or charges made for labor and services, which at the time of purchase would have qualified for exemption under RCW 82.08.02565; and
- 32 (b) Machinery and equipment which at the time of first use would 33 have qualified for exemption under RCW 82.12.02565.
- NEW SECTION. Sec. 6. Chapter 82.32 RCW applies to the administration of this chapter.

12

1314

15 16

17

18 19

2021

2223

24

25

2627

28

2930

- NEW SECTION. Sec. 7. Applications received by the department under this chapter are not confidential and are subject to disclosure.
- 3 <u>NEW SECTION.</u> **Sec. 8.** A new section is added to chapter 82.32 RCW 4 to read as follows:

7

8

9

10 11

12

13

16

17

18 19

20

21

2223

24

2526

27

28

- (1) For the purposes of this section, "biotechnology product and medical device business tax incentive" or "tax incentive" means the sales and use tax deferrals under chapter 82.-- RCW (sections 1 through 7 of this act).
- (2) The legislature finds that accountability and effectiveness are important aspects of setting tax policy. In order to make policy choices regarding the best use of limited state resources, the legislature needs information to evaluate whether the stated goals of legislation were achieved.
- 14 (3) The goals of the biotechnology product and medical device 15 business tax incentives are to:
 - (a) Encourage the creation, expansion, and retention of commercial biotechnology product and medical device manufacturing operations and related job opportunities; and
 - (b) Fully mature the life sciences industry by creating a sustainable commercial sector.
 - (4)(a) A person who receives the benefit of a biotechnology product and medical device business tax incentive shall provide an annual survey to the department. The survey is due by March 31st following any year in which a tax incentive is claimed or used. The survey shall not include names of employees. The survey shall include the amount of the tax incentives claimed or used for the reporting year. The survey shall also include the following information for employment positions in Washington:
 - (i) The number of total employment positions;
- (ii) Full-time, part-time, and temporary employment positions as a percent of total employment;
- (iii) The number of employment positions according to the following wage bands: Less than thirty thousand dollars; thirty thousand dollars or greater, but less than sixty thousand dollars; and sixty thousand dollars or greater. A wage band containing fewer than three individuals may be combined with another wage band; and

- 1 (iv) The number of employment positions that have employer-provided 2 medical, dental, and retirement benefits, by each of the wage bands.
 - (b) The department may request additional information necessary to measure the results of the tax incentive, to be submitted at the same time as the survey.
 - (c) All information collected under this subsection, except the amount of the tax incentive claimed or used, is deemed taxpayer information under RCW 82.32.330 and is not disclosable. Information on the amount of tax incentive claimed or used is not subject to the confidentiality provisions of RCW 82.32.330 and may be disclosed to the public upon request.
 - (5) The department shall use the information from this section to prepare summary descriptive statistics by category. No fewer than three taxpayers shall be included in any category. The department shall report these statistics to the legislature each year by September 1st.
 - (6) If a person fails to submit an annual survey under subsection (4)(a) of this section by the due date of the survey, the department shall declare 12.5 percent of the deferred tax from the date of deferral to be immediately due and payable. Excise taxes payable under this subsection are subject to interest but not penalties, as provided under this chapter. This information is not subject to the confidentiality provisions of RCW 82.32.330 and may be disclosed to the public upon request.
 - (7) The department shall use the information to study the tax incentive specified in subsection (1) of this section. The department shall report to the legislature by December 1, 2009, and December 1, The reports shall measure the number of new biotechnology product and medical device manufacturing facilities established in Washington, the amount of investment in biotechnology product and medical device manufacturing facilities, the number of facilities and investment by firms that utilized the biotechnology product and medical device business tax incentive, the number of biotechnology product and medical device manufacturing jobs in these facilities, the wages and for biotechnology product benefits paid and medical manufacturing jobs, and the wages and benefits of biotechnology product and medical device manufacturing jobs compared to wages and benefits of other manufacturing jobs and jobs in other economic sectors.

4 5

6 7

8

9

10 11

12

13

14

15 16

17

18

19 20

2122

2324

25

2627

28

29

3031

32

33

34

35

3637

1 **Sec. 9.** RCW 82.32.600 and 2005 c 514 s 1002 are each amended to 2 read as follows:

3

4 5

6 7

8

10

11

1213

14

15

- (1) Persons required to file surveys under RCW 82.04.4452 must electronically file with the department all surveys, returns, and any other forms or information the department requires in an electronic format as provided or approved by the department, unless the department grants relief under subsection (2) of this section. As used in this section, "returns" has the same meaning as "return" in RCW 82.32.050.
- (2) Upon request, the department may relieve a person of the obligations in subsection (1) of this section if the person's taxes have been reduced a cumulative total of less than one thousand dollars from all of the credits, exemptions, or preferential business and occupation tax rates, for which a person is required to file an annual survey under RCW 82.04.4452, 82.32.535, 82.32.545, 82.32.570, 82.32.560, 82.60.070, ((ex)) 82.63.020, or section 8 of this act.
- 16 (3) Persons who no longer qualify for relief under subsection (2) 17 of this section will be notified in writing by the department and must 18 comply with subsection (1) of this section by the date provided in the 19 notice.
- 20 (4) Any survey, return, or any other form or information required 21 to be filed in an electronic format under subsection (1) of this 22 section is not filed until received by the department in an electronic 23 format.
- NEW SECTION. Sec. 10. This act takes effect July 1, 2006.
- NEW SECTION. Sec. 11. Sections 1 through 7 of this act constitute a new chapter in Title 82 RCW.
- NEW SECTION. Sec. 12. If any provision of this act or its application to any person or circumstance is held invalid, the remainder of the act or the application of the provision to other persons or circumstances is not affected.

Passed by the House February 10, 2006. Passed by the Senate March 8, 2006. Approved by the Governor March 23, 2006. Filed in Office of Secretary of State March 23, 2006.